Gene Therapy Incorporates Molecular Rheostat For Controlled, Long-Term Drug Delivery

Using a unique combination of innovative technologies, scientists have demonstrated the ability to introduce therapeutic genes into the body and then, further, to precisely control the activity of those genes with a drug that could be given as a simple pill.

The novel gene therapy system, developed by researchers at the University of Pennsylvania Medical Center and ARIAD Pharmaceuticals in Cambridge, MA, represents an entirely new form of drug delivery, one that opens the door to many therapies not previously possible. A report on the experimental study, performed in mice and monkeys, will appear in the January 1, 1999, issue of Science. (Copies of the final version of the paper are available to reporters through the journal's news office at 202-326-6421.)

"We're excited about these results, because they create many new opportunities for experimental and then clinical applications of gene therapy that we couldn't consider before," says James M. Wilson, MD, PhD, director of the Institute for Human Gene Therapy at Penn and senior author on the report. "This system will allow us to modulate the expression of a delivered gene in response to changes in a patient's disease."

The new system couples advances at Penn allowing the long-term introduction of genes into the body with a patented technology (ARGENT) to regulate gene activity from ARIAD.

As the culmination of several years of concerted effort, Penn researchers recently succeeded in optimizing a gene therapy viral vector to achieve long-term protein production without sparking an immune-system reaction. The vector is an engineered version of a virus known as adeno-associated virus, or AAV, which is a very small, innocuous virus.

For this project, the Penn and ARIAD scientists stripped two AAVs of their viral genes and reloaded them respectively with the gene for erythropoietin, or Epo, a recombinant protein that stimulates red blood cell product

Contact: Franklin Hoke
University of Pennsylvania School of Medicine

Page: 1 2 3

Related biology news :

1. 1st International Conference on Cell Therapy for Cardiovascular Disease
2. National Cancer Gene Therapy Foundation gives $4.0 million in research grants
3. Braunschweig Prize 2003 for Molecular Cancer Therapy
4. Alliance for Cancer Gene Therapy announces $1.5 million in national grants to young investigators
5. New research on safety of intracoronary delivery of adenovector reported in cover story of Molecular Therapy
6. Therapy hinders AIDS virus from evolving drug resistance, Hopkins researchers find
7. Invitation To Cover: American Society Of Gene Therapy Meeting
8. Gene Therapy For Pain
9. Role Of Protein Linked To Colon Cancer Identified, Offering Potential Target For Therapy
10. Shock Therapy Exceeds Expectations In Cleaning Up Contaminated Soils
11. Penn Researchers Develop Gene Therapy Technique That Reverses Muscle Membrane Weakness In Muscular Dystrophy Variant

Post Your Comments:

(Date:5/30/2020)... ... May 29, 2020 , ... ... for enterprises globally, has collaborated with EchoNous Inc. to develop the cloud-based connected ... measure systolic heart function, which has been clinically tested versus expert measurements, yielding ...
(Date:5/26/2020)... ... May 26, 2020 , ... ... R&D, today announced that Gritstone Oncology, Inc., a clinical-stage biotechnology company developing ... engagers and TCR-based therapeutics, has implemented Genedata Biologics ® within their ...
(Date:5/21/2020)... ... 2020 , ... Law Enforcement has always been a highly stressful career – ... of these men and women put them constantly in harm’s way both from the ... have always had to face very high daily stress. Now, COVID-19 introduces another even ...
Breaking Biology News(10 mins):
(Date:5/26/2020)... ... 2020 , ... Brilliant , the leading smart home control and lighting ... announce a new integration to bring more convenience, simplicity, and security to the smart ... Connect® can now be controlled from Brilliant’s in-wall touchscreen control panels and mobile app. ...
(Date:5/21/2020)... ... May 20, 2020 , ... ... Simon Prakash, who will serve as the company’s executive vice president of product ... when Exo is disrupting the medical imaging space, bringing more than 24 years ...
(Date:5/15/2020)... ... 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches ... Mr. Ganz will continue to lead Sentien’s Board of Directors, a role he has ... Miller and Sentien’s management team. , Mr. Ganz has more than 30 ...
(Date:5/14/2020)... ... May 13, 2020 , ... Early stages of drug discovery ... no information on the drug’s mechanism of action (MOA). Gene expression profiling technologies ... the activity of molecular pathways. This information can complement phenotypic readouts and can ...
Breaking Biology Technology:
Cached News: